Lymphoma: Hodgkin's and Non-Hodgkin's

Lymphoma is a malignancy of the lymphatic system — a network of tissues and organs that produces, stores, and carries white blood cells throughout the body. This page covers the two principal categories of lymphoma, Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), including how each develops at a cellular level, the clinical scenarios in which they present, and the diagnostic and treatment boundaries that distinguish management pathways. Understanding these distinctions matters because staging, prognosis, and treatment selection differ substantially between the two families and among their subtypes.

Definition and scope

Lymphoma originates when lymphocytes — B cells, T cells, or natural killer (NK) cells — undergo malignant transformation and proliferate in an uncontrolled manner. The lymphatic system spans lymph nodes, the spleen, thymus, bone marrow, and lymphatic vessels, meaning lymphoma can arise at virtually any anatomic site. The National Cancer Institute (NCI) classifies lymphoma as the sixth most commonly diagnosed cancer type in the United States, with non-Hodgkin's lymphoma accounting for roughly 80,550 new cases estimated for a recent reporting year versus approximately 8,570 new cases of Hodgkin's lymphoma (NCI SEER Program).

The dividing line between the two categories is histological: Hodgkin's lymphoma is defined by the presence of Reed-Sternberg cells — large, binucleated or multinucleated B-cell derivatives that carry a characteristic "owl-eye" morphology. Any lymphoma lacking Reed-Sternberg cells is, by definition, classified as non-Hodgkin's lymphoma. This single pathological criterion is the foundation of the entire diagnostic taxonomy, as described in the World Health Organization (WHO) Classification of Haematolymphoid Tumours (5th edition).

Understanding the broader landscape of cancer biology helps contextualize why lymphoma's classification system is built around cellular morphology and immunophenotyping rather than anatomic location alone. The regulatory context for oncology, including FDA approval pathways for lymphoma therapeutics, shapes which treatment options are available at each disease stage.

How it works

Hodgkin's Lymphoma: Mechanism and Subtypes

In classical Hodgkin's lymphoma, the malignant Reed-Sternberg cell derives from a germinal center B lymphocyte that has lost the ability to express surface immunoglobulin yet evades programmed cell death. The Reed-Sternberg cell secretes cytokines — including interleukin-5, interleukin-10, and TGF-β — that recruit an inflammatory microenvironment of eosinophils, plasma cells, and fibrotic tissue, producing the characteristic reactive background seen on biopsy.

WHO classification recognizes five HL subtypes:

Nodular sclerosis — Most common, comprising approximately 70% of HL cases; characterized by collagen bands and lacunar Reed-Sternberg variants.
Mixed cellularity — Second most common; associated with Epstein-Barr virus (EBV) in a significant proportion of cases.
Lymphocyte-rich — Least aggressive classical subtype; background of abundant reactive lymphocytes.
Lymphocyte-depleted — Rarest classical subtype; higher proportion of Reed-Sternberg cells, often associated with advanced disease.
Nodular lymphocyte-predominant HL (NLPHL) — Distinct entity; tumor cells called "popcorn cells" express CD20, unlike classical HL cells.

Non-Hodgkin's Lymphoma: Mechanism and Subtypes

NHL encompasses more than 60 distinct disease entities under WHO classification, arising from B cells (approximately 85% of cases), T cells, or NK cells. The malignant transformation typically involves chromosomal translocations, oncogene activation, or failure of apoptotic pathways.

Two broad functional categories organize clinical decision-making:

Indolent (slow-growing) NHL — Examples include follicular lymphoma and marginal zone lymphoma. These often remain asymptomatic for extended periods but are generally considered incurable with standard chemotherapy.
Aggressive (fast-growing) NHL — Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive subtype, representing approximately 30–35% of all NHL diagnoses (NCI). DLBCL is potentially curable with combination chemoimmunotherapy.

The bone marrow and stem cell transplant pathway is integrated into treatment planning for relapsed or refractory disease in both HL and NHL. CAR T-cell therapy has received FDA approval for specific relapsed/refractory large B-cell lymphoma indications, representing a structural shift in third-line treatment options.

Common scenarios

Lymphoma presents across a wide age spectrum. Hodgkin's lymphoma displays a bimodal age distribution: one peak between ages 15 and 35, and a second peak after age 55. Non-Hodgkin's lymphoma incidence increases steadily with age, with median diagnosis age exceeding 65 years for most subtypes (NCI SEER).

Typical clinical presentations include:

Painless lymphadenopathy — Persistent, rubbery, enlarged lymph nodes in the cervical, axillary, or inguinal regions that do not resolve over weeks.
B symptoms — Fever exceeding 38°C, drenching night sweats, and unintentional weight loss exceeding 10% of body weight in 6 months; presence of B symptoms advances Ann Arbor staging and influences prognosis.
Mediastinal mass — Particularly common in nodular sclerosis HL; may present as cough, dyspnea, or superior vena cava syndrome.
Extranodal involvement — More characteristic of NHL; primary CNS lymphoma, gastric MALT lymphoma, and cutaneous T-cell lymphoma represent extranodal presentations with distinct management protocols.
Incidental discovery — Splenomegaly or mediastinal widening found on imaging performed for unrelated reasons.

Evaluation of persistent unexplained weight loss or fatigue is a recognized entry point into the lymphoma diagnostic workup when accompanied by lymphadenopathy.

Decision boundaries

Staging under the Lugano Classification (revised from the Ann Arbor system) assigns stages I through IV based on number of nodal regions involved, laterality relative to the diaphragm, and presence of extranodal extension (Lugano Classification, Journal of Clinical Oncology, 2014).

Key decision thresholds:

Factor	Hodgkin's Lymphoma	Non-Hodgkin's Lymphoma
Definitive diagnosis	Reed-Sternberg cells on biopsy	Immunophenotyping by flow cytometry and IHC
First-line treatment (localized)	ABVD chemotherapy ± radiation	Depends on subtype; R-CHOP for DLBCL
First-line treatment (advanced)	BEACOPP or BV-AVD regimens	R-CHOP or watchful waiting for indolent NHL
Cure expectation	High in early-stage disease (~90% 5-year survival for Stage I/II, per NCI)	Variable; DLBCL ~60–65% curable; follicular lymphoma generally not curable with chemotherapy
PET-CT response assessment	Standard at interim and end of treatment	Indicated for FDG-avid subtypes

Molecular profiling and biomarker analysis have expanded staging and risk-stratification capabilities, particularly for DLBCL where cell-of-origin (germinal center B-cell vs. activated B-cell subtype by Hans algorithm) predicts chemotherapy response. Genetic testing and counseling is relevant for patients with familial clustering or specific germline predisposition syndromes.

Clinical trials represent a structured option at multiple decision points — initial therapy, relapsed/refractory disease, and maintenance — and are catalogued through the NCI Clinical Trials database. The FDA's oncology approvals are tracked through the FDA Hematology/Oncology Approvals portal, which documents indication-specific approvals including brentuximab vedotin for HL and axicabtagene ciloleucel for DLBCL.

Pathology reports are the authoritative document type at the center of every lymphoma classification decision, integrating morphology, immunohistochemistry, flow cytometry, cytogenetics, and molecular findings into a single diagnostic conclusion.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)